SYLVANT (siltuximab), monoclonal antibody
RARE DISEASE - New medicinal product
Opinions on drugs - Posted on Jun 03 2015
Reason for request
Minor clinical benefit in the management of multicentric Castleman’s disease in adults not infected with HIV and HHV-8
- SYLVANT is the first medicinal product with Marketing Authorisation in the treatment of adult patients with multicentric Castleman’s disease (MCD) not infected with human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8)
- In these patients, it has shown its efficacy in terms of tumour response (partial and complete).
- Clinical efficacy data remain limited and have not shown any gain in overall survival.
Clinical Added Value
Évaluation des médicaments